Eagle Pharmaceuticals to Host Third Quarter 2021 Financial Results on November 9, 2021

Rhea-AI Summary

Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) will release its 2021 third quarter financial results on November 9, 2021, before the market opens. CEO Scott Tarriff and CFO Brian Cahill will host a conference call on the same day at 8:30 a.m. ET to discuss the results. Investors can access the call via a toll-free U.S. number or internationally, as well as through a live and archived webcast available on the company's website. Eagle Pharmaceuticals is dedicated to innovative medicine development, with a portfolio including RYANODEX® and BENDEKA®.

Positive

• Scheduled release of Q3 financial results indicates transparency and accountability to investors.
• Conference call allows direct communication between management and shareholders.

Negative

• None.

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 third quarter financial results on Tuesday, November 9, 2021, before the market opens.

Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows:

Date	Tuesday, November 9, 2021
Time	8:30 a.m. ET
Toll free (U.S.)	866-342-8591
International	203-518-9822
Webcast (live and replay)	www.eagleus.com, under the “Investor Relations” section

A replay of the conference call will be available for one week after the call's completion by dialing 800-839-8292 (US) or 402-220-6069 (International) and entering conference call ID EGRXQ321. The webcast will be archived for 30 days at the aforementioned URL.

About Eagle Pharmaceuticals, Inc.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include RYANODEX^®, BENDEKA^®, BELRAPZO^®, and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211028006236/en/

Investor Relations for Eagle Pharmaceuticals, Inc:

Lisa M. Wilson

T: 212-452-2793

E: lwilson@insitecony.com

Source: Eagle Pharmaceuticals, Inc.

FAQ

When will Eagle Pharmaceuticals release its third quarter 2021 financial results?

Eagle Pharmaceuticals will release its third quarter 2021 financial results on November 9, 2021, before the market opens.

What time is the conference call for Eagle Pharmaceuticals' Q3 results?

The conference call for Eagle Pharmaceuticals' Q3 results is scheduled for 8:30 a.m. ET on November 9, 2021.

How can I access the Eagle Pharmaceuticals Q3 conference call?

You can access the Eagle Pharmaceuticals Q3 conference call by dialing the toll-free U.S. number 866-342-8591 or the international number 203-518-9822.

Where can I find the archived webcast of the Eagle Pharmaceuticals conference call?

The archived webcast of the Eagle Pharmaceuticals conference call will be available for 30 days on the company's website under the 'Investor Relations' section.